T. Rowe Price Associates
VIVO

T. Rowe Price Associates’s Meridian Bioscience Inc VIVO Stock Holding History

T. Rowe Price Associates’s Portfolio VIVO Stock Details VIVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-27,215
Closed -$904K – 3003
2022
Q4 		$904K Sell
27,215
-800
-3% -$25.8K ﹤0.01% 1822
2022
Q3 		$884K Buy
28,015
+1,336
+5% +$43.3K ﹤0.01% 1820
2022
Q2 		$812K Sell
26,679
-8,931
-25% -$242K ﹤0.01% 1986
2022
Q1 		$924K Buy
35,610
+2,302
+7% +$54.8K ﹤0.01% 2049
2021
Q4 		$679K Sell
33,308
-2,600
-7% -$49.9K ﹤0.01% 2236
2021
Q3 		$691K Hold
35,908
– – ﹤0.01% 2226
2021
Q2 		$796K Buy
35,908
+793
+2% +$16.8K ﹤0.01% 2165
2021
Q1 		$922K Buy
35,115
+2,693
+8% +$64K ﹤0.01% 2096
2020
Q4 		$606K Buy
32,422
+390
+1% +$7.28K ﹤0.01% 2171
2020
Q3 		$544K Buy
32,032
+14,100
+79% +$274K ﹤0.01% 2060
2020
Q2 		$418K Buy
17,932
+195
+1% +$2.83K ﹤0.01% 2123
2020
Q1 		$149K Buy
17,737
+210
+1% +$1.77K ﹤0.01% 2366
2019
Q4 		$171K Buy
17,527
+1,669
+11% +$15.7K ﹤0.01% 2421
2019
Q3 		$150K Buy
15,858
+191
+1% +$2.01K ﹤0.01% 2417
2019
Q2 		$186K Buy
15,667
+131
+0.8% +$1.58K ﹤0.01% 2417
2019
Q1 		$274K Buy
15,536
+100
+0.6% +$1.66K ﹤0.01% 2322
2018
Q4 		$268K Buy
+15,436
New +$263K ﹤0.01% 2334
2018
Q1 		– Sell
-11,491
Closed -$161K – 2599
2017
Q4 		$161K Buy
+11,491
New +$168K ﹤0.01% 2454
2017
Q1 		– Sell
-1,004,555
Closed -$17.8M – 2604
2016
Q4 		$17.8M Sell
1,004,555
-1,488,480
-60% -$26.1M ﹤0.01% 1176
2016
Q3 		$48.1M Sell
2,493,035
-33,460
-1% -$655K 0.01% 817
2016
Q2 		$49.3M Sell
2,526,495
-18,080
-0.7% -$355K 0.01% 788
2016
Q1 		$52.4M Sell
2,544,575
-38,580
-1% -$760K 0.01% 757
2015
Q4 		$53M Buy
2,583,155
+47,070
+2% +$902K 0.01% 746
2015
Q3 		$43.4M Sell
2,536,085
-30,460
-1% -$557K 0.01% 815
2015
Q2 		$47.8M Sell
2,566,545
-4,900
-0.2% -$90.9K 0.01% 854
2015
Q1 		$49.1M Sell
2,571,445
-100,560
-4% -$1.86M 0.01% 852
2014
Q4 		$44M Buy
2,672,005
+43,100
+2% +$739K 0.01% 886
2014
Q3 		$46.5M Buy
2,628,905
+71,600
+3% +$1.41M 0.01% 856
2014
Q2 		$52.8M Sell
2,557,305
-75,030
-3% -$1.54M 0.01% 850
2014
Q1 		$57.4M Sell
2,632,335
-5,650
-0.2% -$130K 0.01% 815
2013
Q4 		$70M Sell
2,637,985
-420,360
-14% -$10.3M 0.02% 718
2013
Q3 		$72.3M Buy
3,058,345
+7,470
+0.2% +$174K 0.02% 682
2013
Q2 		$65.6M Buy
+3,050,875
New +$65.8M 0.02% 695

Other funds holding VIVO

BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

T. Rowe Price Associates's VIVO Position: Q1 2023 in Review

T. Rowe Price Associates sold out of Meridian Bioscience Inc (VIVO) in Q1 2023, closing a stake of 27,215 shares — an estimated $904K sold.

T. Rowe Price Associates first reported a position in VIVO in Q2 2013 and held it in 33 quarters. The position peaked at $72.3M in Q3 2013. 2 funds tracked by Wall St. Rank hold VIVO as of Q1 2023.

  • T. Rowe Price Associates reported no remaining Meridian Bioscience Inc position as of Q1 2023 after selling out during the quarter.
  • T. Rowe Price Associates sold 27,215 Meridian Bioscience Inc shares in Q1 2023, an estimated $904K.
  • T. Rowe Price Associates first reported a position in Meridian Bioscience Inc in Q2 2013 and held it in 33 quarters.
  • T. Rowe Price Associates's Meridian Bioscience Inc position peaked at $72.3M in Q3 2013.
  • 2 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q1 2023.

Based on T. Rowe Price Associates's 13F filing for Q1 2023, filed 15 May 2023.